PMC:7796072 / 5740-9301
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"192","span":{"begin":422,"end":425},"obj":"Gene"},{"id":"193","span":{"begin":2790,"end":2793},"obj":"Gene"},{"id":"194","span":{"begin":2358,"end":2361},"obj":"Gene"},{"id":"195","span":{"begin":1922,"end":1925},"obj":"Gene"},{"id":"196","span":{"begin":1519,"end":1522},"obj":"Gene"},{"id":"197","span":{"begin":1416,"end":1419},"obj":"Gene"},{"id":"198","span":{"begin":1208,"end":1211},"obj":"Gene"},{"id":"199","span":{"begin":934,"end":937},"obj":"Gene"},{"id":"200","span":{"begin":878,"end":881},"obj":"Gene"},{"id":"201","span":{"begin":565,"end":568},"obj":"Gene"},{"id":"202","span":{"begin":125,"end":128},"obj":"Gene"},{"id":"203","span":{"begin":2091,"end":2099},"obj":"Species"},{"id":"204","span":{"begin":2159,"end":2164},"obj":"Species"},{"id":"205","span":{"begin":2165,"end":2177},"obj":"Species"},{"id":"206","span":{"begin":2183,"end":2205},"obj":"Species"},{"id":"207","span":{"begin":2482,"end":2490},"obj":"Species"},{"id":"208","span":{"begin":129,"end":140},"obj":"Disease"},{"id":"209","span":{"begin":216,"end":224},"obj":"Disease"},{"id":"210","span":{"begin":225,"end":235},"obj":"Disease"},{"id":"211","span":{"begin":267,"end":275},"obj":"Disease"},{"id":"212","span":{"begin":276,"end":286},"obj":"Disease"},{"id":"213","span":{"begin":636,"end":654},"obj":"Disease"},{"id":"214","span":{"begin":729,"end":737},"obj":"Disease"},{"id":"215","span":{"begin":738,"end":744},"obj":"Disease"},{"id":"216","span":{"begin":770,"end":781},"obj":"Disease"},{"id":"217","span":{"begin":845,"end":856},"obj":"Disease"},{"id":"218","span":{"begin":1019,"end":1032},"obj":"Disease"},{"id":"219","span":{"begin":1037,"end":1042},"obj":"Disease"},{"id":"220","span":{"begin":1150,"end":1158},"obj":"Disease"},{"id":"221","span":{"begin":1159,"end":1168},"obj":"Disease"},{"id":"222","span":{"begin":1489,"end":1500},"obj":"Disease"},{"id":"223","span":{"begin":1564,"end":1572},"obj":"Disease"},{"id":"224","span":{"begin":1615,"end":1620},"obj":"Disease"},{"id":"225","span":{"begin":1926,"end":1937},"obj":"Disease"},{"id":"226","span":{"begin":1971,"end":2022},"obj":"Disease"},{"id":"227","span":{"begin":2076,"end":2090},"obj":"Disease"},{"id":"228","span":{"begin":2206,"end":2215},"obj":"Disease"},{"id":"229","span":{"begin":2250,"end":2259},"obj":"Disease"},{"id":"230","span":{"begin":2276,"end":2285},"obj":"Disease"},{"id":"231","span":{"begin":2635,"end":2643},"obj":"Disease"},{"id":"232","span":{"begin":2676,"end":2683},"obj":"Disease"},{"id":"233","span":{"begin":2749,"end":2757},"obj":"Disease"},{"id":"234","span":{"begin":2758,"end":2767},"obj":"Disease"},{"id":"235","span":{"begin":2772,"end":2777},"obj":"Disease"},{"id":"236","span":{"begin":2794,"end":2805},"obj":"Disease"},{"id":"237","span":{"begin":2900,"end":2908},"obj":"Disease"},{"id":"238","span":{"begin":2997,"end":3015},"obj":"Disease"},{"id":"239","span":{"begin":3066,"end":3074},"obj":"Disease"},{"id":"240","span":{"begin":3082,"end":3093},"obj":"Disease"},{"id":"241","span":{"begin":3139,"end":3150},"obj":"Disease"},{"id":"242","span":{"begin":3195,"end":3203},"obj":"Disease"},{"id":"243","span":{"begin":3460,"end":3468},"obj":"Disease"}],"attributes":[{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"Gene:3046"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"Gene:3046"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"Gene:3046"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"Gene:3046"},{"id":"A196","pred":"tao:has_database_id","subj":"196","obj":"Gene:3046"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"Gene:3046"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"Gene:3046"},{"id":"A199","pred":"tao:has_database_id","subj":"199","obj":"Gene:3046"},{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"Gene:3046"},{"id":"A201","pred":"tao:has_database_id","subj":"201","obj":"Gene:3046"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"Gene:3046"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"Tax:9606"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"Tax:9606"},{"id":"A205","pred":"tao:has_database_id","subj":"205","obj":"Tax:12637"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"Tax:11137"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"Tax:9606"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"MESH:D013789"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"MESH:C000657245"},{"id":"A210","pred":"tao:has_database_id","subj":"210","obj":"MESH:D007239"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"MESH:C000657245"},{"id":"A212","pred":"tao:has_database_id","subj":"212","obj":"MESH:D007239"},{"id":"A213","pred":"tao:has_database_id","subj":"213","obj":"MESH:C000657245"},{"id":"A214","pred":"tao:has_database_id","subj":"214","obj":"MESH:C000657245"},{"id":"A215","pred":"tao:has_database_id","subj":"215","obj":"MESH:D003643"},{"id":"A216","pred":"tao:has_database_id","subj":"216","obj":"MESH:D013789"},{"id":"A217","pred":"tao:has_database_id","subj":"217","obj":"MESH:D013789"},{"id":"A218","pred":"tao:has_database_id","subj":"218","obj":"MESH:D007239"},{"id":"A219","pred":"tao:has_database_id","subj":"219","obj":"MESH:D003643"},{"id":"A220","pred":"tao:has_database_id","subj":"220","obj":"MESH:C000657245"},{"id":"A221","pred":"tao:has_database_id","subj":"221","obj":"MESH:D007239"},{"id":"A222","pred":"tao:has_database_id","subj":"222","obj":"MESH:D013789"},{"id":"A223","pred":"tao:has_database_id","subj":"223","obj":"MESH:C000657245"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"MESH:D003643"},{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"MESH:D013789"},{"id":"A226","pred":"tao:has_database_id","subj":"226","obj":"MESH:D005955"},{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"MESH:D005955"},{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"MESH:D007239"},{"id":"A229","pred":"tao:has_database_id","subj":"229","obj":"MESH:D011014"},{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"MESH:D007239"},{"id":"A231","pred":"tao:has_database_id","subj":"231","obj":"MESH:C000657245"},{"id":"A232","pred":"tao:has_database_id","subj":"232","obj":"MESH:D008133"},{"id":"A233","pred":"tao:has_database_id","subj":"233","obj":"MESH:C000657245"},{"id":"A234","pred":"tao:has_database_id","subj":"234","obj":"MESH:D007239"},{"id":"A235","pred":"tao:has_database_id","subj":"235","obj":"MESH:D003643"},{"id":"A236","pred":"tao:has_database_id","subj":"236","obj":"MESH:D013789"},{"id":"A237","pred":"tao:has_database_id","subj":"237","obj":"MESH:C000657245"},{"id":"A238","pred":"tao:has_database_id","subj":"238","obj":"MESH:D006453"},{"id":"A239","pred":"tao:has_database_id","subj":"239","obj":"MESH:C000657245"},{"id":"A240","pred":"tao:has_database_id","subj":"240","obj":"MESH:D013789"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"MESH:D013789"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"MESH:C000657245"},{"id":"A243","pred":"tao:has_database_id","subj":"243","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Intriguing epidemiological observations suggest, and biological evidence supports, an inverse correlation between increasing HbE/thalassemia trait prevalence rates and decreased susceptibility to, and fatality from, COVID-19 infections (Table 1, Figures 1, 2). Local COVID-19 infections within Thailand vary 6-fold between the northeast (2.84% of total cases) versus the south (19%), in tandem with regional variations in HbE gene frequency (70% in the northeast compared to 12% in the south) [3,13,25]. Similarly, Malaysia, which borders southern Thailand, has an HbE trait frequency of only 3.8% [26] but reports substantially higher COVID19 infections compared to Thailand [4]. Interestingly, in Cambodia and Laos (where zero COVID-19 deaths are reported) (Table 1), thalassemia mutation rates are similar to Thailand [13]; for Cambodia, the thalassemia prevalence is 62.7% (HbE being the most prevalent, at 56%) [27]. In Myanmar (HbE carrier rates vary between 1.9 and 42% depending on ethnic group and geography), low infection and death rates are also seen (Table 1) [28]. Vietnam and the neighboring Chinese province of Yunnan both report low COVID-19 infection rates, with locally high prevalence of HbE trait in line with other mainland SE Asian nations (Table 1) [15–24,29–31]. In Vietnam, the Mon-Khmer-speaking ethnic groups are genetically closer to the Thai-Lao-Cambodian border populations and report HbE gene prevalence up to 36% [29]. Singapore, where the prevalence of β-thalassemia trait is 0.9% and HbE trait is 0.55% [32], was severely hit by COVID-19 compared to neighboring Thailand, but the death rates were very low [4]. The high number of cases in Singapore seems to stem from clusters in male migrant workers living in close proximity in crowded living quarters, promoting higher infectious spread [33]. These migrant workers are from various ethnic groups (e.g., Bengali and Tamil) with higher HbE/thalassemia trait prevalence but also higher glucose-6-phosphate dehydrogenase (G6PD) deficiency rates, compared to resident Singaporeans [32,34,35]. G6PD-deficient patients have been shown to be highly susceptible to enteroviruses, human dengue virus, and human coronavirus 229E infection. They also tend to develop severe pneumonia after microbial infection [36]. Consequently, close proximity overrides the protective effects of HbE and/or selectively potentiates the risk to infect the ones without the hypothetically protective trait, especially from patients carrying a higher viral load. Thailand’s and Singapore’s effective 14-day quarantine policy of all arrivals have now virtually eradicated local COVID-19 cases [37]. In the remainder of SE Asia and South Asian territories, the trend continues with increasing COVID-19 infection and death rates where HbE/thalassemia trait prevalence is low (Table 1, Figures 1, 2) [14–23]. In Brazil, a country severely hit by COVID-19, despite heavy early Italian migrations, less than 2% of Brazilian blood donors exhibit hemoglobinopathies [38]. Similarly, Spain, also severely affected by COVID-19, has a thalassemia trait of only 0.92% [39]. Despite its higher thalassemia trait prevalence, Italy was severely hit by COVID-19, initially in Lombardy, with a traditionally low carrier rate compared to islands and coastal areas [40]. Greece [40] and Cyprus [41], with an effective lock-down, a distancing strategy, and a higher, homogenous carrier rate, seem to be experiencing lower COVID-19 rates compared to their European peers, even during the second wave (Table 1, Figures 1, 2)."}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":2250,"end":2259},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Intriguing epidemiological observations suggest, and biological evidence supports, an inverse correlation between increasing HbE/thalassemia trait prevalence rates and decreased susceptibility to, and fatality from, COVID-19 infections (Table 1, Figures 1, 2). Local COVID-19 infections within Thailand vary 6-fold between the northeast (2.84% of total cases) versus the south (19%), in tandem with regional variations in HbE gene frequency (70% in the northeast compared to 12% in the south) [3,13,25]. Similarly, Malaysia, which borders southern Thailand, has an HbE trait frequency of only 3.8% [26] but reports substantially higher COVID19 infections compared to Thailand [4]. Interestingly, in Cambodia and Laos (where zero COVID-19 deaths are reported) (Table 1), thalassemia mutation rates are similar to Thailand [13]; for Cambodia, the thalassemia prevalence is 62.7% (HbE being the most prevalent, at 56%) [27]. In Myanmar (HbE carrier rates vary between 1.9 and 42% depending on ethnic group and geography), low infection and death rates are also seen (Table 1) [28]. Vietnam and the neighboring Chinese province of Yunnan both report low COVID-19 infection rates, with locally high prevalence of HbE trait in line with other mainland SE Asian nations (Table 1) [15–24,29–31]. In Vietnam, the Mon-Khmer-speaking ethnic groups are genetically closer to the Thai-Lao-Cambodian border populations and report HbE gene prevalence up to 36% [29]. Singapore, where the prevalence of β-thalassemia trait is 0.9% and HbE trait is 0.55% [32], was severely hit by COVID-19 compared to neighboring Thailand, but the death rates were very low [4]. The high number of cases in Singapore seems to stem from clusters in male migrant workers living in close proximity in crowded living quarters, promoting higher infectious spread [33]. These migrant workers are from various ethnic groups (e.g., Bengali and Tamil) with higher HbE/thalassemia trait prevalence but also higher glucose-6-phosphate dehydrogenase (G6PD) deficiency rates, compared to resident Singaporeans [32,34,35]. G6PD-deficient patients have been shown to be highly susceptible to enteroviruses, human dengue virus, and human coronavirus 229E infection. They also tend to develop severe pneumonia after microbial infection [36]. Consequently, close proximity overrides the protective effects of HbE and/or selectively potentiates the risk to infect the ones without the hypothetically protective trait, especially from patients carrying a higher viral load. Thailand’s and Singapore’s effective 14-day quarantine policy of all arrivals have now virtually eradicated local COVID-19 cases [37]. In the remainder of SE Asia and South Asian territories, the trend continues with increasing COVID-19 infection and death rates where HbE/thalassemia trait prevalence is low (Table 1, Figures 1, 2) [14–23]. In Brazil, a country severely hit by COVID-19, despite heavy early Italian migrations, less than 2% of Brazilian blood donors exhibit hemoglobinopathies [38]. Similarly, Spain, also severely affected by COVID-19, has a thalassemia trait of only 0.92% [39]. Despite its higher thalassemia trait prevalence, Italy was severely hit by COVID-19, initially in Lombardy, with a traditionally low carrier rate compared to islands and coastal areas [40]. Greece [40] and Cyprus [41], with an effective lock-down, a distancing strategy, and a higher, homogenous carrier rate, seem to be experiencing lower COVID-19 rates compared to their European peers, even during the second wave (Table 1, Figures 1, 2)."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T44","span":{"begin":0,"end":260},"obj":"Sentence"},{"id":"T45","span":{"begin":261,"end":503},"obj":"Sentence"},{"id":"T46","span":{"begin":504,"end":680},"obj":"Sentence"},{"id":"T47","span":{"begin":681,"end":921},"obj":"Sentence"},{"id":"T48","span":{"begin":922,"end":1078},"obj":"Sentence"},{"id":"T49","span":{"begin":1079,"end":1287},"obj":"Sentence"},{"id":"T50","span":{"begin":1288,"end":1451},"obj":"Sentence"},{"id":"T51","span":{"begin":1452,"end":1645},"obj":"Sentence"},{"id":"T52","span":{"begin":1646,"end":1830},"obj":"Sentence"},{"id":"T53","span":{"begin":1831,"end":2075},"obj":"Sentence"},{"id":"T54","span":{"begin":2076,"end":2216},"obj":"Sentence"},{"id":"T55","span":{"begin":2217,"end":2291},"obj":"Sentence"},{"id":"T56","span":{"begin":2292,"end":2520},"obj":"Sentence"},{"id":"T57","span":{"begin":2521,"end":2655},"obj":"Sentence"},{"id":"T58","span":{"begin":2656,"end":2862},"obj":"Sentence"},{"id":"T59","span":{"begin":2863,"end":3021},"obj":"Sentence"},{"id":"T60","span":{"begin":3022,"end":3119},"obj":"Sentence"},{"id":"T61","span":{"begin":3120,"end":3309},"obj":"Sentence"},{"id":"T62","span":{"begin":3310,"end":3561},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Intriguing epidemiological observations suggest, and biological evidence supports, an inverse correlation between increasing HbE/thalassemia trait prevalence rates and decreased susceptibility to, and fatality from, COVID-19 infections (Table 1, Figures 1, 2). Local COVID-19 infections within Thailand vary 6-fold between the northeast (2.84% of total cases) versus the south (19%), in tandem with regional variations in HbE gene frequency (70% in the northeast compared to 12% in the south) [3,13,25]. Similarly, Malaysia, which borders southern Thailand, has an HbE trait frequency of only 3.8% [26] but reports substantially higher COVID19 infections compared to Thailand [4]. Interestingly, in Cambodia and Laos (where zero COVID-19 deaths are reported) (Table 1), thalassemia mutation rates are similar to Thailand [13]; for Cambodia, the thalassemia prevalence is 62.7% (HbE being the most prevalent, at 56%) [27]. In Myanmar (HbE carrier rates vary between 1.9 and 42% depending on ethnic group and geography), low infection and death rates are also seen (Table 1) [28]. Vietnam and the neighboring Chinese province of Yunnan both report low COVID-19 infection rates, with locally high prevalence of HbE trait in line with other mainland SE Asian nations (Table 1) [15–24,29–31]. In Vietnam, the Mon-Khmer-speaking ethnic groups are genetically closer to the Thai-Lao-Cambodian border populations and report HbE gene prevalence up to 36% [29]. Singapore, where the prevalence of β-thalassemia trait is 0.9% and HbE trait is 0.55% [32], was severely hit by COVID-19 compared to neighboring Thailand, but the death rates were very low [4]. The high number of cases in Singapore seems to stem from clusters in male migrant workers living in close proximity in crowded living quarters, promoting higher infectious spread [33]. These migrant workers are from various ethnic groups (e.g., Bengali and Tamil) with higher HbE/thalassemia trait prevalence but also higher glucose-6-phosphate dehydrogenase (G6PD) deficiency rates, compared to resident Singaporeans [32,34,35]. G6PD-deficient patients have been shown to be highly susceptible to enteroviruses, human dengue virus, and human coronavirus 229E infection. They also tend to develop severe pneumonia after microbial infection [36]. Consequently, close proximity overrides the protective effects of HbE and/or selectively potentiates the risk to infect the ones without the hypothetically protective trait, especially from patients carrying a higher viral load. Thailand’s and Singapore’s effective 14-day quarantine policy of all arrivals have now virtually eradicated local COVID-19 cases [37]. In the remainder of SE Asia and South Asian territories, the trend continues with increasing COVID-19 infection and death rates where HbE/thalassemia trait prevalence is low (Table 1, Figures 1, 2) [14–23]. In Brazil, a country severely hit by COVID-19, despite heavy early Italian migrations, less than 2% of Brazilian blood donors exhibit hemoglobinopathies [38]. Similarly, Spain, also severely affected by COVID-19, has a thalassemia trait of only 0.92% [39]. Despite its higher thalassemia trait prevalence, Italy was severely hit by COVID-19, initially in Lombardy, with a traditionally low carrier rate compared to islands and coastal areas [40]. Greece [40] and Cyprus [41], with an effective lock-down, a distancing strategy, and a higher, homogenous carrier rate, seem to be experiencing lower COVID-19 rates compared to their European peers, even during the second wave (Table 1, Figures 1, 2)."}